Ganga Pharmaceuticals Limited has appointed M/s. Deepak Jedhe & Co as its Internal Auditor for the financial year 2026-27. The decision was taken by the Board of Directors during its meeting held on May 21, 2026, following the recommendation of the Audit Committee.

Appointment Details

The appointment is effective immediately, covering the upcoming financial year. M/s. Deepak Jedhe & Co, a firm of Chartered Accountants, will assume the responsibilities of Internal Auditor to ensure compliance and robust internal controls within the organization.

Auditor Profile

M/s. Deepak Jedhe & Co is a professional firm established in 2015. It provides a range of services including Assurance, Taxation, and Advisory. The firm is backed by over a decade of experience and emphasizes strong professional ethics and technical expertise to deliver value-driven solutions to its clients.

Key Information

The Board meeting commenced at 03:30 p.m. and concluded at 4:00 p.m. on the same day. The disclosure regarding this appointment has been made in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Ganga Pharmaceuticals Limited announced its audited financial results for the fiscal year ended March 31, 2026, on May 21, 2026. The Board of Directors approved the standalone financial results, which show an improvement in profitability and revenue for the full year. The statutory auditors, Banka & Banka, issued an audit report with an unmodified opinion on the annual financial results.

Financial Performance Overview

For the financial year ended March 31, 2026, the company reported a net profit of ₹10.15 lakh, compared to ₹7.90 lakh in the previous year. Revenue from operations rose to ₹282.79 lakh from ₹263.74 lakh in FY25. Total income for the period was ₹310.70 lakh, slightly higher than the ₹307.33 lakh recorded in the preceding year.

The half-year performance ending March 31, 2026, also reflected growth. Net profit for this half-year stood at ₹7.67 lakh, while revenue from operations reached ₹146.14 lakh. Total expenses for the full year increased marginally to ₹297.77 lakh from ₹297.86 lakh in the previous year.

Key Financial Metrics

The company’s earnings per share (EPS) for the full year improved to ₹0.17 on a basic and diluted basis, up from ₹0.16 and ₹0.12 respectively in the prior year. The paid-up equity share capital increased significantly to ₹591.15 lakh as of March 31, 2026, from ₹483.65 lakh in the previous year, following the conversion of warrants.

Capital Structure and Cash Flows

During the current reporting period, Ganga Pharmaceuticals raised ₹112.88 lakh through the conversion of 10,75,000 warrants. Of this amount, ₹98.39 lakh was utilized for the objects stated in the issue document by March 31, 2026, with the unutilized balance of ₹14.48 lakh held in bank accounts.

The cash flow statement for the year ended March 31, 2026, revealed a net decrease in cash and cash equivalents of ₹24.42 lakh. Cash and cash equivalents at the end of the year stood at ₹5.82 lakh, comprising ₹1.38 lakh in cash on hand and ₹4.44 lakh in bank balances.